NCT04315246 2022-07-15177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)Y-mAbs TherapeuticsPhase 1/2 Withdrawn